SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells

Oncogene

Volumn 32, Issue 5, 2013, Pages 589-598

  Wang, Z ^a,b   Yuan, H ^a,b   Roth, M ^a   Stark, J M ^a   Bhatia, R ^a   Chen, W Y ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

acquired resistance; BCR ABL; chronic myelogenous leukemia; DNA damage repair; mutation; SIRT1

Indexed keywords

BCR ABL PROTEIN; CAMPTOTHECIN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; SIRTUIN 1;

APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIRTUIN 1;

EID: 84873408603     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.83     Document Type: Article

References (58)

1. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441 - 453. (Pubitemid 46823444)
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408 - 2417. (Pubitemid 44903745)
3. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003; 55: 401 - 423. (Pubitemid 37013211)
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876 - 880. (Pubitemid 32743979)
5. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCRABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117 - 125. (Pubitemid 41039112)
6. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129 - 141. (Pubitemid 40248339)
7. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006; 108: 1328 - 1333. (Pubitemid 44232032)
8. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399 - 401. (Pubitemid 38938156)
9. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542 - 2551. (Pubitemid 43882350)
10. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531 - 2541. (Pubitemid 43882349)
11. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267 - 1270. (Pubitemid 40943094)
12. Yuan H, Wang Z, Gao C, Chen W, Huang Q, Yee JK et al. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem 2010; 285: 5085 - 5096.
13. Guarente L. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 2007; 72: 483 - 488.
14. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403: 795 - 800. (Pubitemid 30111843)
15. Vaquero A, Scher M, Erdjument-Bromage H, Tempst P, Serrano L, Reinberg D. SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature 2007; 450: 440 - 444. (Pubitemid 350126745)
16. Bosch-Presegue L, Raurell-Vila H, Marazuela-Duque A, Kane-Goldsmith N, Valle A, Oliver J et al. Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and ensures genome protection. Mol Cell 2011; 42: 210 - 223.
17. O'Hagan HM, Mohammad HP, Baylin SB. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet 2008; 4: e1000155.
18. Oberdoerffer P, Michan S, McVay M, Mostoslavsky R, Vann J, Park SK et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008; 135: 907 - 918.
19. Yuan Z, Zhang X, Sengupta N, Lane WS, Seto E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell 2007; 27: 149 - 162. (Pubitemid 46991383)
20. Li K, Casta A, Wang R, Lozada E, Fan W, Kane S et al. Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation. J Biol Chem 2008; 283: 7590 - 7598.
21. Ming M, Shea CR, Guo X, Li X, Soltani K, Han W et al. Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C. Proc Natl Acad Sci USA 2010; 107: 22623 - 22628.
22. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008; 14: 312 - 323.
23. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137 - 148. (Pubitemid 33035941)
24. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149 - 159. (Pubitemid 33035942)
25. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390 - 392. (Pubitemid 38938153)
26. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551 - 563. (Pubitemid 38264432)
27. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011 - 2015. (Pubitemid 38393275)
28. Daitoku H, Hatta M, Matsuzaki H, Aratani S, Ohshima T, Miyagishi M et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci USA 2004; 101: 10042 - 10047. (Pubitemid 38891191)
29. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005; 123: 437 - 448. (Pubitemid 41546674)
30. Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA, Baylin SB. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 1997; 57: 1678 - 1681. (Pubitemid 27199658)
31. Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 2012; 119: 1904 - 1914.
32. Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011; 25: 226 - 235.
33. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 2003; 63: 2118-2126. (Pubitemid 36538615)
34. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2006; 12: 5869 - 5878. (Pubitemid 44629620)
35. Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010; 17: 427 - 442.
36. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006; 6: 789 - 802. (Pubitemid 44450467)
37. Wang B, Hasan MK, Alvarado E, Yuan H, Wu H, Chen WY. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 2011; 30: 907 - 921.
38. Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem. 2009; 284: 3823 - 3832.
39. Gaymes TJ, Padua RA, Pla M, Orr S, Omidvar N, Chomienne C et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 2006; 4: 563 - 573. (Pubitemid 44341366)
40. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8: 795 - 806. (Pubitemid 33030213)
41. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen speciesdependent DNA double-strand breaks. Blood 2004; 104: 3746 - 3753. (Pubitemid 39564453)
42. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001; 27: 247 - 254. (Pubitemid 32201842)
43. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004; 13: 627 - 638. (Pubitemid 38368121)
44. Bennardo N, Cheng A, Huang N, Stark JM. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 2008; 4: e1000110.
45. Weinstock DM, Nakanishi K, Helgadottir HR, Jasin M. Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase. Methods Enzymol 2006; 409: 524 - 540.
46. Rass E, Grabarz A, Plo I, Gautier J, Bertrand P, Lopez BS. Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. Nat Struct Mol Biol 2009; 16: 819 - 824.
47. Dinkelmann M, Spehalski E, Stoneham T, Buis J, Wu Y, Sekiguchi JM et al. Multiple functions of MRN in end-joining pathways during isotype class switching. Nat Struct Mol Biol 2009; 16: 808 - 813.
48. Xie A, Kwok A, Scully R. Role of mammalian Mre11 in classical and alternative nonhomologous end joining. Nat Struct Mol Biol 2009; 16: 814 - 818.
49. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010; 120: 2254 - 2264.
50. Seluanov A, Mittelman D, Pereira-Smith OM, Wilson JH, Gorbunova V. DNA end joining becomes less efficient and more error-prone during cellular senescence. Proc Natl Acad Sci USA 2004; 101: 7624 - 7629. (Pubitemid 38658079)
51. Slupianek A, Nowicki MO, Koptyra M, Skorski T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair (Amst) 2006; 5: 243 - 250. (Pubitemid 43069524)
52. Chen WY, Yuan H, Wang Z. De novo acquisition of BCR-ABL mutations for CML acquired resistance. In: Koschmieder S, Krug U (eds). Myeloid Leukemia: Basic Mechanisms of Leukemogenesis. INTECH, Rijeka, Croatia, 2011. pp 69 - 84.
53. Brady N, Gaymes TJ, Cheung M, Mufti GJ, Rassool FV. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res 2003; 63: 1798 - 1805. (Pubitemid 36460840)
54. Gaymes TJ, Mufti GJ, Rassool FV. Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res 2002; 62: 2791 - 2797. (Pubitemid 34525762)
55. Kharbanda S, Pandey P, Jin S, Inoue S, Bharti A, Yuan ZM et al. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 1997; 386: 732 - 735. (Pubitemid 27193496)
56. Jin S, Kharbanda S, Mayer B, Kufe D, Weaver DT. Binding of Ku and c-Abl at the kinase homology region of DNA-dependent protein kinase catalytic subunit. J Biol Chem 1997; 272: 24763 - 24766. (Pubitemid 27415644)
57. Richardson C, Jasin M. Coupled homologous and nonhomologous repair of a double-strand break preserves genomic integrity in mammalian cells. Mol Cell Biol 2000; 20: 9068 - 9075. (Pubitemid 32245935)
58. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006; 312: 1175 - 1178. (Pubitemid 43801135)